{
    "nctId": "NCT05366699",
    "briefTitle": "LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy",
    "officialTitle": "A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy",
    "overallStatus": "SUSPENDED",
    "conditions": "Lymphedema, Breast Cancer, Lymphedema",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Lymphatic flow pattern of whole limb",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ages 18 to 75 years (inclusive)\n* Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy\n* Free of distant metastasis in preoperative screening\n* Histology results of axillary lymph nodes could be either Negative or Positive\n* Patients who undergo preoperative chemotherapy can be included\n* Willingness and ability to provide written informed consent\n* Willingness and ability to comply with all study procedures\n\nExclusion Criteria:\n\n* Primary lymphedema of the affected upper limb\n* Secondary lymphedema of the affected limb prior to the lymphadenectomy\n* Radiotherapy at the axilla before the study / surgery\n* Allergic reaction to porcine collagen or ICG\n* Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery\n* Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening\n* Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis\n* Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion)\n* Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\\>1.1 or R0 bioimpedance ratio \\> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk.\n* Life expectancy \\< 2 years for any reason\n* Pregnancy or nursing\n* Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n* Severe psychiatric disease\n* Significant or chronic renal insufficiency (defined as serum creatinine \\> 2.5 mg/dL or an estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL/min at screening) or requires dialytic support\n* Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \\> 3 \u00d7 upper limit of the normal range (ULN) and/or bilirubin level \\> 2 \u00d7 ULN at screening\n* Absolute neutrophil count \\< 1500 mm3 at screening\n* Hemoglobin concentration \\< 9 g/dL at screening\n* Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}